Enzalutamide
Who holds supplier records for Enzalutamide? 29 organisations hold a current record for Enzalutamide: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (17), China (6), Netherlands (2), Taiwan (1) and 1 other country (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Enzalutamide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/enzalutamide
Reading the evidence
- 29 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
17 of the 27 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 17 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Enzalutamide expires 23 Feb 2037. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (29)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Enzalutamide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 29117, 41429 · latest filing Mar 2025
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 30304, 34489 · latest filing Dec 2019
- AARTI PHARMALABS LIMITEDIndiaActive DMF 35618 · latest filing Apr 2021
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 43204 · latest filing Dec 2025
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 39103 · latest filing Dec 2023
- AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD)IndiaActive DMF 43581 · latest filing Feb 2026
- Aurisco Pharmaceutical Co.,ltdChina Company GMP cert on recordActive DMF 34886 · latest filing Jun 2020
- BDR LIFESCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 40067 · latest filing Sept 2024
- Biocon LimitedIndiaActive DMF 42622 · latest filing Sept 2025
- CDYMAX (INDIA) PHARMA PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 37904 · latest filing Dec 2022
- CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTDChinaActive DMF 41569 · latest filing Apr 2025
- Cipla LimitedIndia Company GMP cert on recordActive DMF 35143 · latest filing Sept 2020
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 36053 · latest filing Oct 2021
- JIANGSU HANSOH PHARMACEUTICAL CO LTDActive DMF 39853 · latest filing Sept 2024
- Jiangxi Kvvit Pharmaceutical Co., Ltd.ChinaActive DMF 37148 · latest filing May 2022
- Laurus Labs LimitedIndia Company GMP cert on recordActive DMF 31196 · latest filing Dec 2016
- LEE FINE CHEM PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 43981 · latest filing Mar 2026
- Macleods Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 41145 · latest filing Feb 2025
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 30279 · latest filing Feb 2016
- SABA ILAC SANAYI VE TICARET ASActive DMF 43773 · latest filing Mar 2026
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 30644, 38335 · latest filing Aug 2023
- Shandong Anhong Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 38592 · latest filing Aug 2023
- SHILPA PHARMA LIFESCIENCES LTDIndiaActive DMF 30260 · latest filing Mar 2016
- Sichuan Kelun Pharmaceutical Co., Ltd.ChinaActive DMF 40999 · latest filing Dec 2024
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 36896 · latest filing Mar 2022
- SynthonNetherlands Company GMP cert on recordActive DMF 36447 · latest filing Oct 2021
- TAPI NL BVNetherlandsActive DMF 29872 · latest filing May 2016
- Zakłady Farmaceutyczne Polpharma S.A.Poland Company GMP cert on recordActive DMF 39560 · latest filing Apr 2024
- Zhejiang Jingsheng Pharmaceutical Co., Ltd.ChinaActive DMF 39955 · latest filing Jun 2024
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Enzalutamide are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- MYLAN LABORATORIES LTDInactive DMF 30010 · filed Nov 2015
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (5 listed products contain Enzalutamide). The latest listed patent expires 23 Feb 2037. The latest listed exclusivity ended 17 Nov 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Enzalutamide is an androgen receptor inhibitor used primarily in the treatment of metastatic castration-resistant prostate cancer. It works by blocking the action of male hormones that fuel the growth of cancer cells in the prostate.
Chemical identity
- IUPAC name
- 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
- Canonical SMILES
- CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
- InChIKey
- WXCXUHSOUPDCQV-UHFFFAOYSA-N
- Synonyms
- Xtandi API, mdv 3100, mdv-3100, mdv3100, xtandi
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Androgen Receptor Inhibitor
- Mechanism of action
- Androgen Receptor Antagonists; Cytochrome P450 2C19 Inducers; Cytochrome P450 2C9 Inducers; Cytochrome P450 3A4 Inducers
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Enzalutamide?
29 organisations hold an active US FDA Type II Drug Master File or a CEP for Enzalutamide: Dr. Reddy's Laboratories Ltd. (India), Zydus Lifesciences Limited (India), AARTI PHARMALABS LIMITED (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (India), Aurisco Pharmaceutical Co.,ltd (China) and BDR LIFESCIENCES PRIVATE LIMITED (India), and 21 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Enzalutamide Drug Master Files are active?
Dr. Reddy's Laboratories Ltd. (DMF 29117, 41429), Zydus Lifesciences Limited (DMF 30304, 34489), AARTI PHARMALABS LIMITED (DMF 35618), Alembic Pharmaceuticals Limited (DMF 43204), ALIVUS LIFE SCIENCES LTD (DMF 39103), AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (DMF 43581), Aurisco Pharmaceutical Co.,ltd (DMF 34886) and BDR LIFESCIENCES PRIVATE LIMITED (DMF 40067) and 21 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Enzalutamide records mean?
1 organisation has only inactive Type II DMFs for Enzalutamide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Enzalutamide?
Yes. The latest patent listed for an approved US product containing Enzalutamide expires 23 Feb 2037, across 5 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Enzalutamide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Enzalutamide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.